SuperworthSarepta Therapeutics free cash flow SRPT
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $196.5M
- −14% on a year earlier
- Fiscal year 2024
- −$342.7M
Sarepta Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $196.5M, down 14% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2024 | −$342.7M | n/a |
| FY2023 | −$577.1M | n/a |
| FY2022 | −$356.2M | n/a |
| FY2021 | −$481.7M | −2007% |
| FY2020 | $25.3M | n/a |
| FY2019 | −$516.1M | n/a |
| FY2018 | −$449.8M | n/a |
| FY2017 | −$244M | n/a |
| FY2016 | −$251.2M | n/a |
| FY2015 | −$152.9M | n/a |
| FY2014 | −$154M | n/a |
| FY2013 | −$67.1M | n/a |
| FY2012 | −$29.8M | n/a |
| FY2011 | −$24.9M | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $196.5M | −14% | n/a | |
| Q1 FY26 | −$204.8M | n/a | n/a | |
| Q3 FY25 | −$37.5M | n/a | −$381.1M | |
| Q2 FY25 | $229.5M | n/a | −$451.5M | |
| Q1 FY25 | −$627.1M | n/a | −$695.3M | |
| Q4 FY24 | $54M | n/a | −$342.7M | |
| Q3 FY24 | −$108M | n/a | −$470.4M | |
| Q2 FY24 | −$14.2M | n/a | −$506.8M | |
| Q1 FY24 | −$274.5M | n/a | −$632.7M | |
| Q4 FY23 | −$73.7M | n/a | −$577.1M | |
| Q3 FY23 | −$144.4M | n/a | −$603.8M | |
| Q2 FY23 | −$140.1M | n/a | −$532.6M |
Against its peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| SRPTSarepta Therapeutics | n/m |
| ANIPANI Pharmaceuticals | 10.4% |
| HRMYHarmony Biosciences | n/m |
| PAHCPhibro Animal Health | 0.6% |
| PBHPrestige Consumer Healthcare | 10.4% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 12.4% |
| NRIXNurix Therapeutics | 13.4% |
| OMEROmeros | −5.7% |
| AMPHAmphastar Pharmaceuticals | 14.3% |
| OGNOrganon | 15.7% |
| Peer median | 11.4% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Sarepta Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.